Recent News and Updates

Read the December blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to catch up on impactful updates for the AACE Community. In this month’s highlights, Johnnie reflects on an incredible year at AACE.

AACE President, Susan L. Samson, MD, PhD, FRCPC, FACE, shares key updates from the October 25-26, 2024, Board of Directors and Board of Trustees meeting, including new updates about AACE journals, international growth, committee updates, and much more.

We are seeking candidates for an Associate Editor role for our new Gold Open Access journal (formerly AACE Clinical Case Reports), to be launched in Spring 2025. Learn about the duties, responsibilities, and requirements to apply.

Read the November blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to catch up on impactful updates for the AACE community. This month’s highlights feature advocacy initiatives, AACE Annual Meeting 2025 registration, new award opportunities, and exciting global initiatives.

The results of the AACE 2024 Election for open AACE Officer and Board positions for 2025 are now available. Thank you to the members of the Nominating Committee for their objective and in-depth evaluation of the excellent candidates submitted for consideration.

Read the October blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to explore valuable resources that enhance your practice and patient care. This month's highlights include global conferences, membership benefits, complimentary advocacy training, and rare disease webinars—all designed to support our community.

AACE President, Susan L. Samson, MD, PhD, FRCPC, FACE, shares key updates from the August 15, 2024, Board of Directors and Board of Trustees meeting, including new awards, membership benefits, and clinical practice guideline approvals.

Read the September blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to learn about membership engagement initiatives, our prestigious FACE designation, 2025 AACE elections, the call for Annual Meeting poster abstracts, and our upcoming advocacy training program.

Read the August blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to learn about the latest advocacy efforts, new patient journey resources, recent community discussions, and how to become a vaccine champion.

Read the July blog from AACE CEO Johnnie White, MBA, CAE, CMP Fellow, to learn about new membership updates, upcoming global events, recent news, and advocacy efforts.

Read the June blog by AACE CEO, Johnnie White, MBA, CAE, CMP Fellow, to learn about our new Community Platform interest groups, the latest developments in our CDC and CMSS partnerships, Certificate Programs, and other exciting initiatives.

AACE CEO, Johnnie White, MBA, CAE, CMP Fellow, shares a recap of our 2024 Annual Meeting in New Orleans. Discover the key takeaways from pivotal sessions, engaging meet-ups, the President’s Party, and other significant highlights that shaped this year's event.

Endorsed by AACE, and represented by Scott Isaacs, MD, FACP, FACE, the Innovations in Steatotic Liver Disease (SLD) Think-Tank was held in Barcelona, Spain on May 3-4, 2024. Discover the key outcomes, including policy recommendations, economic implications, technological advancements, social issues, and international insights.

In his first month as AACE's Chief Executive Officer, Johnnie White, MBA, CAE, CMP Fellow, provides insights about his onboarding journey and strategic vision for growth. Read his community update to learn about upcoming initiatives to advance the field of clinical endocrinology and improve global health.

Call for chair, vice chair, authors, and a methodology fellow to participate in development of an AACE Clinical Practice Guideline Update on the Management of Persons with Postmenopausal Osteoporosis

Call for chair, vice chair, authors, and a methodology fellow to participate in development of an AACE Consensus Statement on Diabetes Technology.

We're thrilled to introduce our new AACE Chief Executive Officer, Johnnie White, MBA, CAE, CMP Fellow! Please join us in celebrating this exciting new chapter as we also bid a fond farewell to our Interim CEO, Suzanne Berry, MBA, CAE.

The National Academy of Medicine (NAM) Scholars in Diagnostic Excellence call for applications is now open until March 1. Learn how to apply and become part of the growing cadre of national leaders to advance diagnostic excellence and improve health for all.

Discover exciting updates for the year ahead from AACE President, Susan L. Samson, MD, PhD, FRCPC, FACE.

A thank you message from Immediate Past President Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE, to our esteemed Board of Directors, Executive Committee, Executive Leadership Team, dedicated staff, and the countless volunteers whose passion helps us fulfill our mission to elevating the practice of clinical endocrinology to improve global health.

AACE announced the appointment of Johnnie White, MBA, CAE, CMP as Chief Executive Officer, effective March 1, 2024. "We are extremely pleased to have Mr. White join AACE as our Chief Executive Officer," said Susan L. Samson, MD, PhD, FRCPC, FACE, President-Elect of AACE and Chair of the CEO Search Committee. "Mr. White brings deep leadership experience in professional associations and societies, as well as within the endocrinology specialty itself."

AACE is pleased to announce the appointment of Johnnie White, MBA, CAE, CMP, as Chief Executive Officer, effective March 1, 2024. White brings over 30 years of results-focused association leadership experience, including successful tenures at national healthcare societies and experience working with and advocating for endocrinologists and other endocrine care team professionals.

Vaccination rates are lagging this year for flu, Covid, and RSV. The CDC has developed key messages and tools for health care providers to use in this final 2023 effort to protect patients before they gather with family and friends for the holidays. Learn about key vaccination messages and access tools from the CDC.

Great news! — AACE was highlighted in the American Medical Association (AMA) Health Equity in Organized Medicine Report for our Diversity, Equity, and Inclusion (DEI) efforts. View the report and how our DEI survey results have contributed to changes within our organization.

AvoMD, a software platform that brings clinical evidence into the workflow to help clinicians streamline decisions and save time, has announced a strategic partnership with the American Association of Clinical Endocrinology (AACE). This collaboration aims to integrate AACE's comprehensive guidelines into the AvoMD platform to provide seamless access to the latest evidence-based endocrinology recommendations at the point-of-care.

AACE and the American Thyroid Association (ATA) have become increasingly alarmed about the negative impacts of the reduction of RVU for the “Fine Needle Aspiration” CPT code set 10005, 10006 and 10021 that began with the 2019 Physician Fee Schedule. We ask that the Centers for Medicare & Medicaid Services (CMS) review its previous decision to reduce payment for these codes now that we have further experience with the new valuation.

The American Medical Association (AMA) is undertaking a new national study supported by AACE, along with 172 healthcare organizations, to collect representative data on physician practice expenses. Learn how this study will serve as an opportunity to communicate accurate financial information to policymakers, including members of Congress and the Centers for Medicare & Medicaid Services.

The American Association of Clinical Endocrinology (AACE) is pleased to announce that it has retained Suzanne Berry, MBA, CAE, to serve as the Interim Chief Executive Officer. The board and the staff look forward to working with her closely in achieving our mission: Elevating the Practice of Clinical Endocrinology to Improve Global Health.

Former member of AACE Board of Directors and Board of Trustees Aaron I. Vinik, MD, PhD, FCP, MACP, FACE, passed away peacefully June 15, 2023, in his home in Norfolk, VA. Dr. Vinik served AACE in a variety of roles and capacities, including in development of several AACE Annual Meetings, Disease State Networks, and previous versions of our AACE Diabetes Guideline.

The American Medical Association (AMA) House of Delegates passed the resolution to keep the government out of the examination room regarding gender affirming care after AACE and other Endocrine Section Council delegates advocated for the AMA to oppose all criminal and legal penalties against patients and their families seeking gender affirming care.

This new algorithm provides concise guidance to assist health care professionals with clinical decision-making for the management of persons with type 2 diabetes mellitus and related comorbidities and complications.

Greetings AACE Community,

As we celebrate the success of our Annual Meeting in Seattle, on behalf of our Board of Directors, we would like to announce the appointment of Suzanne Berry, CAE, as the Interim CEO of AACE.

Call for vice chair, authors, and a methodology fellow to participate in updating the AACE Algorithm for the Management of Persons with Dyslipidemia.

On March 31, 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), released the Calendar Year (CY) 2024 Medicare Advantage (MA) and Part D Rate Announcement that finalized payment policies for these programs. Read our federal policy update to learn about the 2024 rate announcement, updates to Medicare, Medicaid, and more.

On February 16, 2023, President Biden signed a notice announcing the final extension of the Public Health Emergency (PHE) with a termination date of May 11, 2023. Read our federal policy blog update to learn about the termination of the Public Health Emergency (PHE) policy and its implications, as well as updates on the FTC allegations against GoodRx, economic data, and Medicare Advantage enrollment.

On February 1, 2023, the U.S. House of Representatives passed H. J. Res. 7, by a vote of 229-197 (7 not voting). This bill would terminate the COVID-19 National Emergency and the Public Health Emergency (PHE) immediately. Read our federal policy blog to learn about the significant changes.

On December 29, 2022, the President signed the Consolidated Appropriations Act, 2023 [P.L. 117-328]. Read our federal policy blog to learn about the key items in the new law.

In compliance with Chapter 6 of the AACE Bylaws*, this Memorandum serves to officially notify you in writing that the Board of Directors, upon an affirmative 2/3 vote, approved the AACE Nominating Committee slate of candidates for the special election for AACE President Elect, Treasurer and Secretary for a one-year term to begin January 1, 2023, and end on December 31, 2023.

The Centers for Medicare and Medicaid Services (CMS) released the CY 2023 physician fee schedule final rule, hospital outpatient prospective payment system, and ambulatory surgical center payment rule. Read our November 2022 federal policy blog to learn about the updates.

In February, 2022, AACE supported an urgent call for action to address the serious health delivery issues that patients with diabetes were facing in the Tigray Region of Ethiopia as a result of the ongoing conflict between the Federal Government and the Tigray Regional Government. We are deeply concerned about the ongoing barriers to delivering life-saving supplies and medications to innocent people of Tigray, suffering with diabetes. Read our full statement to learn more.

Dear Colleague,

On behalf of the AACE Nominating Committee, we invite your participation in the nomination process for candidates for a special election for open AACE Officer positions for 2023.

The recent bylaws amendments approved by the Board of Directors affecting elections include:

Statement: Medical Care Team – Patient Relationship

Benefits of Continuous Glucose Monitoring 

• Insights into effects of food, exercise, illness and medication on real-time diabetes management 
• Improved Time in Range (TIR) 
• Directional arrows 
• Audible alarm

A bipartisan group of eight House lawmakers, spearheaded by Reps. Ami Bera (D-CA) and Larry Bucshon (R-IN), are asking stakeholders how to fix the flawed Medicare Access and CHIP Reauthorization Act without dramatically increasing Medicare spending. The legislators ask for creative legislative or regulatory solutions to Medicare’s pay instability.  Below you will find the link to their letter requesting information.

Submit your paper for presentation at the first annual Endocrine Practice Journal Symposium at the 2023 AACE Annual Meeting in Seattle, WA.

Read the July 2022 federal policy update to learn about the Centers for Medicare and Medicaid Services (CMS) newly released proposed 2023 Medicare physician fee schedule rule

Read the July 2022 federal policy update to learn about the results of the June 28th House Committee on Energy and Commerce Subcommittee on Oversight and Investigation hearing on “Protecting America's Seniors: Oversight of Private Sector Medicare Advantage Plans."

The Council of Medical Specialty Societies (CMSS), a coalition of 48 specialty societies (including AACE), strongly denounces any interference into the practice of medicine that undermines the integrity of the patient-physician relationship.

We're seeking chairs, authors, and a methodology fellow to develop a consensus statement on acromegaly. Learn how to apply today!

We're seeking authors and a methodology fellow to update the 2017 AACE Clinical Practice Guideline for the Management of Dyslipidemia and Prevention of Cardiovascular Disease. Learn how to apply today!

Read the June 2022 federal policy update to learn about interchangeable biological products from the FDA, the latest enrollment figures for Medicare, Medicaid, and CHIP released by the CMS, house republican health policy proposals, 2022 social security and Medicare trustees’ reports, and more.

Congratulations to our 2022 Awards, MACE and FACE recipients. All recipients were honored during our 2022 Annual Meeting.

In this update on federal policy in health care, read about the rules and other items that are under OIRA review, the recent pharmacy benefit managers Congressional hearing, and more.

Check out these great resources at AACE!

AACE has been named one of seven subspecialty societies to participate in a Centers for Disease Control and Prevention (CDC)-funded grant project led and coordinated through the Council for Medical Specialty Societies to help increase COVID-19, influenza, and routine vaccinations in high-risk adults with chronic medical conditions.

Congratulations to the newly elected Officers and Board Members! We are confident that AACE will be well served by their contributions.

We at AACE strongly believe that decisions impacting health care of endocrine patients are best left to the health professional, the patient, and the patient’s families for all medical care. Read our position statement on transgender and gender diverse patients to learn more.

The current continuing resolution funds the Federal government until February 18, 2022. The House and Senate Appropriations Committees Chairs and Ranking Members continue their negotiations. Learn about the latest updates on the Congressional Budget Office Report, No Surprises Billing Information, President’s Stimulus Bill, and much more.

There is a severe shortage of diabetes medicines in the Tigray region of Ethiopia, jeopardizing thousands of persons with diabetes. We urge both government organizations and non-government organizations, including manufacturers to strive to improve access to life-saving treatments for diabetes in the Tigray region. Read our full statement to learn more.

Former AACE President, Daniel S. Duick, MD, FACP, MACE, ECNU, passed peacefully, surrounded by family on January 5, 2022. He was an inspiration to the endocrine community as an endocrinology, diabetes and metabolism specialist with more than 55 years of experience in the medical field.

AACE leadership spent the last year developing our 2022-2025 strategic plan, and one of our three focus areas is patient and public awareness. AACE President Dr. Felice Caldarella shares how we are further expanding and updating our patient and public resources by featuring “AACE Patient Journeys”, along with other new developments including our involvement in helping to obtain Congressional approval for the National Clinical Care Commission (NCCC) recommendations on diabetes care, and more.

On December 3, 2021, President Biden signed the "Further Extending Government Funding Act". Public Law 117-70 funds the Federal government through February 18, 2022. It is likely Congress will again consolidate all the bills into one large appropriations bill. The big question is whether Congress can achieve an agreement on full year appropriations or simply pass another continuing resolution.

On November 19th, the U.S. House of Representatives passed H.R. 5376, the “Build Back Better Act”. Learn about the new federal policy updates and how it will support the major health care provisions in H.R. 5376.

On November 2, 2021, the U. S. Department of Health and Human Services Centers for Medicare and Medicaid Services released several final Calendar Year 2022 payment rules. Learn how these rules cover physician fee schedule, hospital outpatient and ambulatory surgical centers, and more.

With our recent announcement about the new AACE Communities initiative that will offer regional events at a global scale, we are happy to share that MCI is teaming up with AACE as a regional office to bring educational opportunities and more to areas within Latin America and Asia-Pacific.

After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.

On July 13, 2021, the Centers for Medicare and Medicaid Services (CMS) posted the proposed rule for the 2022 Physician Fee Schedule (PFS) and other Medicare Part B issues. Learn how the results can bring better accessibility, quality, affordability, empowerment, and innovation.

On July 1, 2021, the “No Surprises Act” Interim Final Rule, Part I, was issued. Learn how this announcement is the first in a series of regulations aimed at shielding patients from increased financial hardships stemming from surprise medical bills.

In June the U.S. Supreme Court came to the end of its term. Meanwhile, Congress has begun the budget/appropriations process. Learn about the latest federal policy updates and how it can impact the future of health care.

Monica Agarwal MD, MEHP, FACE, provides her perspectives on the recent FDA approval of Semaglutide as an addition to the therapeutic armamentarium of weight management options for people living with obesity. Learn her key takeaways and how the new injectable semaglutide can support adults living with obesity.

On May 25, the Senate confirmed Chiquita Brooks-LaSure to be the Centers for Medicare and Medicaid Services Administrator by a vote of 55-44. She was sworn in two days later. In her first interview, Brooks-LaSure stated that her top priorities will be to expand health insurance coverage and address health disparities.

On May 28, President Biden released his FY 2022 budget and revenue proposals. Learn about the breakdown of the health care budget proposals.

The COVID-19 pandemic revealed to Federal public policymakers and the general public the need for more health care providers. More importantly, there was a greater realization of a shortage in underserved areas, particularly in certain urban, rural, and Native American settings. Learn how congress is solving the crisis in the health care workforce.

Congratulations to our 2021 Awards, MACE and FACE recipients. All recipients will be honored during our 2021 Annual Meeting.

We have been notified of several fellowship and medical board scams that are targeting physicians by offering a medical certification and/or endocrinology fellowship designation (FACE) from a medical association for a fee.

Congratulations to the newly elected Officers and Board members.

The Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 [Public Law 116-123] authorized the Secretary of Health and Human Services (HHS) to waive statutory requirements with respect to telehealth services under Medicare for the duration of the COVID-19 Public Health Emergency.

Joint Guidance on COVID-19 Vaccination and Osteoporosis Management from the American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinology (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), the International Osteoporosis Foundation (IOF), and the National Osteoporosis Foundation (NOF)  

The COVID-19 pandemic entered a new promising phase when the first vaccines for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became available in late 2020. We at AACE have recommendations for both endocrine patients and care providers.

In compliance with the AACE Bylaws, we’re sharing with you the following preliminary slate of candidates for election to officer positions for a one-year (1) term. For the Board of Directors, there are five (5) open positions for election to a three-year (3) term (2021-2024), one (1) open position for a two-year (2) term (2021-2023), and one (1) open position for a one-year (1) term (2021-2022).  

This World Diabetes Day, we at the American Association of Clinical Endocrinology (AACE) extend our support to those in the endocrine care team who help diabetes patients every day. Now with a new brand and name that more clearly defines AACE as a community of individuals who work together to elevate the practice of clinical endocrinology, we are committed to expanding diabetes education with a more inclusive approach — with endocrinologists leading the way. 

Nominate your colleagues as candidates for election to the AACE Board of Directors to fill terms expiring in 2021. The deadline to submit your recommended nominee is November 20, 2020, 5:00 pm ET.

There are five positions available on the Board for a three-year term, expiring in 2024, and one, one-year seat to fill the unexpired term of Dr. Susan Samson who became Secretary, expiring in 2022. Board members whose current terms expire in 2021 include:

Welcome to the new pro.aace.com! Things look a little different, so you might be wondering where to find all the educational opportunities we have to offer.

For a quick view of the most popular courses, you can scroll through our carousel entitled “Educational Opportunities” located just underneath the AACE mission statement on the home page of pro.aace.com. Simply click the orange arrows below the boxes to browse.

Lilly has launched “Insulin Affordability: Learn. Act. Share.” to encourage those who use Lilly insulin to:  

• Learn about our affordability options 

• Act by visiting insulinaffordability.com or calling the Lilly Diabetes Solution Center 

• Share this important information with others who may benefit from our solutions.  

An update for current AACE members. On October 20, 2020 - we launched a transformed AACE brand and community. While there are a number of changes that were revealed on October 20, here is what you need to know about our direction.

The nomination submission period closes November 20, 2020 at 11:59 pm EST. The 2021 AACE Awards will be presented during AACE's 30th Annual Meeting in May 2021.

We are pleased to announce that new Editors-in-Chief have been selected for both Endocrine Practice and AACE Clinical Case Reports. In addition to this new editorial leadership, we are also announcing a partnership with Elsevier to publish both journals beginning January 1, 2021.

Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.

An update on outcomes of the virtual Annual Business Meeting that occurred on September 11, 2020.

Join us on October 20, 2020 as we launch a new AACE.

AACE is a dynamic organization that is leading the way in the endocrine community with clinical knowledge and experience.

The U.S. Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes.

Read more about thyroid eye disease, including recent research and case studies from Endocrine Practice and AACE Clinical Case Reports.

Drs. Leslie Eldeiry, Scott Isaacs, and Matthew Levine provide an important AACE member update on behalf of the Board of Directors on two upcoming changes regarding our brand and community. These will be further discussed at the Annual Business Meeting on September 11, 2020.

The Annual Business Meeting of the AACE membership will be held via a ZOOM Virtual Conference Call on Friday, September 11, 2020, from 4:00 pm – 5:00 pm EST. Registration is required.

AbbVie has launched a new SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers patients a cash-pay option to receive Synthroid consistently and conveniently.

Here is a round-up of four different online, on-demand courses you can take that will walk you through the guidelines and help you apply them to your practice.

The FACE application period is open until November 2, 2020. Applications will only be accepted online, and eligible candidates must meet the criteria set forth by the FACE Application Committee.

A new policy statement from AACE including background and recommendations for access to diabetes medication and technology

The COVID-19 public health emergency declaration has officially been extended for another 90 days by Health and Human Services. Secretary Alex Azar endorsed the renewal on July 23, just before it was set to expire July 25. 

President Trump signed four executive orders aimed at lowering the prices Americans pay for prescription drugs, including insulin.

AACE is excited to announce 'The Lowdown on Low Blood Sugar' campaign.

In the era of COVID-19, many in-office visits have been able to convert to virtual appointments. Many ask, how is a telemedicine visit different, and how can I get the most from it?

Disclaimer: This message contains paid content from our sponsors. 

We’ve partnered with Beyond Type 1, a nonprofit organization aiming to unite the global diabetes community and provide solutions to improve lives, to develop Armed For Diabetes,* a campaign to educate veterans on how they can gain access to the latest diabetes management tools.

Dr. Sandra Weber, AACE President 2019-2020, and Dr. Howard Lando, AACE President 2020-2021, deliver addresses to the American Association of Clinical Endocrinologists (AACE) community. Introduction by Paul Markowski, AACE CEO.

Organizations responding to "paucity of data” to provide clear guidance for healthcare professionals treating millions of osteoporosis patients.

Though we sadly we couldn't celebrate in person at our 2020 annual congress, we are happy to congratulate our 2020 Awards, MACE and FACE recipients here on AACE.com. All recipients will be honored during the AACE 30th Annual Scientific & Clinical Congress in 2021.

We are pleased to report to you the results of the AACE 2020 elections. Dr. Daniel L. Hurley, Chair of the Nominating Committee, thanks the members of the Nominating Committee for their time and effort evaluating a number of excellent candidates for Officer positions and the Board of Directors and for developing a strong slate of candidates for the 2020 election.

AACE members Gauri Behari, MD, Karyne Vinales, MD, and Ricardo Correa MD, Es.D, share their experience with telemedicine tools both before and after the COVID-19 health crisis.

We continue to think of you during this unprecedented season. While over the last several weeks you have received many helpful pieces of guidance, research, and news updates - today we simply wish to remind you that our priority remains to be you: our members. You are the heart of AACE, and you are our foremost thought that guides anything and everything we do.

Initial research suggests that people with cardiometabolic disease are at increased risk of experiencing complications from infection with COVID-19 and may be more susceptible to contracting the virus.

There is currently no reason to believe that most people with thyroid disease are at increased risk to contract this novel coronavirus or to experience complications. Nevertheless, if thyroid medications are not taken as prescribed, uncontrolled thyroid disease may increase a person’s risk for viral infection and complications.

It is with great sadness that I share the news of Dr. Alan Garber’s passing yesterday on April 9, 2020. Dr. Garber was a Charter Member of AACE, as well as a Past President of both AACE and ACE.

A new $35 co-pay is available through the Lilly Insulin Value Program in response to the COVID-19 crisis in the U.S.

With the novel COVID-19 virus continuing to spread, it is crucial to adhere to the advice from experts and the Centers for Disease Control and Prevention (CDC) to help reduce risk of infection for individuals and the population at large. This is particularly important for people with adrenal insufficiency and people with uncontrolled Cushing’s Syndrome.

At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.

The U.S. Food and Drug Administration has updated the Nutrition Facts label.

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.

AACE releases update on COVID-19 and the risks and recommended preparations for patients with diabetes.

In an effort to limit the spread of the coronavirus, the Trump Administration announced today that it is expanding Medicare telehealth coverage so that beneficiaries can receive healthcare services without having to travel to their physician's office.

AACE invites nominations and applications for two, separate positions:

1) Editor-in-Chief of Endocrine Practice (EP)

2) Editor-in-Chief of AACE Clinical Case Reports (ACCR)

Endocrine Practice (EP) publishes original articles, review articles, commentaries, editorials and visual vignettes. The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.

As the coronavirus (COVID-19) continues to spread in the United States, it is important for everyone to take the necessary precautions to help prevent infection and spread of the virus. While it is difficult to assess the unique implications of COVID-19 in people with diabetes (type 1, type 2, or gestational) at this time, diabetes and other chronic medical conditions can make patients more vulnerable to infections, leading to serious consequences. In addition, uncontrolled diabetes with hyperglycemia is known to impair immune function.

AACE is closely monitoring the information being shared about the virus and will take the precautions needed to promote the health and safety of our staff and members attending the EMBRAACE annual meeting.

Coinciding with World Obesity Day, AACE has joined over 100 medical and scientific organizations across the world in pledging our support for a consensus statement that recognizes unscientific public narratives of obesity as a major cause of weight stigma and calls for strong policies and legislation to prevent weight-based discrimination.

AACE is excited to share all the benefits of this improved system with you.

Due to signals in safety clinical trials showing possible increased risk of cancer, The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market.

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Click to read which models are affected.

The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension and glucose management strategies.

The former American Association of Diabetes Educators is now the Association of Diabetes Care & Education Specialists (ADCES). The rebranding reflects the association’s shift from referencing the specialty title as “diabetes educator” to the more comprehensive “diabetes care and education specialist.”

In compliance with the AACE Bylaws, the AACE Nominating Committee is pleased to notify the membership of the selection of the following preliminary slate of candidates for election to Officer positions for a one-year (1) term.

AACE has released updated guidelines for the perioperative nutrition, metabolic and nonsurgical support of patients undergoing bariatric procedures.

The Physician Fee Schedule for CY 2021 includes an an overall 16 percent increase in E/M codes for Endocrinology – the most of any specialty. A record number of AACE members responded to an AACE “Action Alert” and sent comments to CMS in September in support of the higher valuations – thank you! Unfortunately CMS did NOT place FNA codes on the “potentially mis-valued” list, closing the door to a process to increase these codes, which were substantially reduced this year.

As of January 1, 2019, Medicare will pay separately for a newly defined type of physicians' service termed as, “Brief communication technology-based service, e.g. virtual check-in…" The HCPCs code is G2012 and is defined as,

The Medullary Thyroid Carcinoma (MTC) Registry Consortium* is partnering with the American Thyroid Association® (ATA) to create a registry (list) of adult (18 years of age and older) cases of MTC diagnosed in the United States in order to characterize their medical histories and possible risk factors, including history of treatment with long-acting GLP-1 RAs from January 1, 2010 to present (the MTC Registry).

Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.

The Government Accountability Office (GAO) has released a new study on prescription drug use to treat obesity.

The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.

Medicare imposed substantial cuts in reimbursements for the new and revised fine needle aspiration codes for 2019. AACE, together with the Endocrine Society and American Thyroid Association, advocated for you with letters to Centers for Medicare and Medicaid Services (CMS) and Congress opposing these cuts. We secured a win with the release of the proposed physician pay rule issued July 29. 

Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.

The FACE application period is from Monday, August 12, 2019, 8:00 am ET to Friday, November 01, 2019, 5:00 pm, ET. FACE Applications for 2020 will only be accepted through an online process.

Prasad, M. et al. Triglyceride and Triglyceride/HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease. J Am Heart Assoc. 2019;8:e009442. DOI: 10.1161/JAHA.118.009442.)

Chait, A. and Eckel, R. The Chylomicronemia Syndrome Is Most Often Multifactorial. Ann Intern Med. 2019;170:626-634. doi:10.7326/M19-0203

Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678

Hawley CE, et al. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. Drugs Aging 2019

Kim DW, et al. Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. Diabetology & metabolic syndrome 2019; 11:30

Schleyer T, Hui S, Wang J, et al. Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study. J Manag Care Spec Pharm. 2019;25(5):544-554. 

Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.

In the systematic review and meta-analysis of more than 4,000 patients with adenomas published in the Annals of Internal Medicine (Elhassan et al), authors reported that patients with mild autonomous cortisol secretion or nonfunctioning adrenal adenomas very rarely develop overt hormonal excess (<0.1%). In addition, adenoma growth >1cm occurred only in 2.5% of patients and no patient developed an adrenal malignancy at follow up.

The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.

When it comes to optimal bone health and fracture prevention, there is scant evidence for recommending supplementation with vitamins and minerals other than calcium and vitamin D, according to AACE member Daniel L. Hurley, MD, FACE, who spoke at the AACE 28th Annual Scientific & Clinical Congress.

This year, at the 28th Annual Scientific & Clinical Congress, AACE made changes to the traditional lecture format and pushed for casual presentations, allowing more in-depth and interactive conversations. Read about the change from a member's perspective in this editorial by Archana Sadhu, MD, FACE, longtime Los Angeles resident.

Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking hospital care for diabetic ketoacidosis during the weekend as opposed to during the week may increase mortality risk.

Type 2 diabetes (T2D) is associated with increased risk for fractures in the short term but not in the long term, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28^th Annual Scientific & Clinic

Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

The use of an insulin pump to deliver continuous pulsatile cortisol may be a viable treatment option in patients with severe adrenal insufficiency who are unresponsive to oral corticosteroids, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Biochemical markers and clinical signs and symptoms of endogenous Cushing syndrome improved after 6 months of levoketoconazole therapy, according to phase 3 study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Significantly more euthyroid patients with thyroid disease suffer from anxiety compared with depression, regardless of whether they have Hashimoto thyroiditis autoimmunity, according to research results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress. 

Hypothyroidism is a risk factor for increased length of hospital stay and mortality in patients with congestive heart failure (CHF), according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease, according to phase 3 confirmatory trial data presented at the AACE 28^th Annual Scientific & Clinical Congress.

For indeterminate thyroid nodules following fine needle aspiration, evidence of thick post-microcystic reflection on ultrasound was found to be associated with malignant nodules, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

Lower income and education levels may negatively affect the experience and expectations of patients who are obese who receive care for weight management, according to study results presented at the AACE 28^th Annual Scientific & Clinical Congress.

The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin, according to data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program presented at the AACE 28^th Annual Scientific & Clinical Congress.

Endocrine Today has compiled a list of the top five news stories posted from the American Association of Clinical Endocrinologists Scientific & Clinical Congress, held April 24-28, 2019, in Los Angeles.

Distinctive serum steroid profiles might emerge in patients with adrenal tumors and Cushing's syndrome, according to research reported by Shobana Athimulam, MBBS, of the Mayo Clinic in Rochester, Minnesota, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.

The ThyroSeq v3 Genomic Classifier was able to effectively classify thyroid nodules with samples collected through fine needle aspiration (FNA), according to research reported by Lindsey Tolino, MBA, of the University of Pittsburgh Medical Center in Pennsylvania, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.

The investigational agent teprotumumab was effective for reducing proptosis associated with thyroid eye disease, according to late-breaking phase III data presented by Raymond Douglas, MD, PhD, of Cedars Sinai Medical Center in Los Angeles, and colleagues, at the AACE 28^th Annual Scientific & Clinical Congress.

The investigational agent relacorilant significantly improved excess cortisol in patients with endogenous hypercortisolism, researchers reported at the AACE 28^th Annual Scientific & Clinical Congress.

Among patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28^th Annual Scientific & Clinical Congress.

AACE Member Roy Taylor, MD, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28^th Annual Scientific & Clinical Congress.

AACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28^th Annual Scientific & Clinical Congress.

Lewis E. Braverman, MD, MACE, 89, passed away peacefully on Monday, June 10, 2019. He leaves his wife Mimi Braverman; his sons, William Braverman and Daniel Braverman; and his five grandchildren.

In a recent interview with the AACE2019News.com, Yulino Castillo Núñez, MD, recipient of the 2019 AACE International Clinician Award, discussed some of the greatest influences on his career in endocrinology.

Kevin Pho, MD, is a board-certified internal medicine physician and founder of KevinMD, social media’s leading physician voice. He has been named the web’s top social media influencer in health care and medicine. Dr. Pho is coming to AACE to deliver the keynote address “Social Media and the Physician” on Saturday, April 27. AACE2019News.com recently had the opportunity to ask Dr. Pho a few questions about his presentation, social media and why endocrinologists should get on the social media train.

Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk.

Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503.

Fogacci F, Banach M, Mikhailidis DP et al. Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacol Res. 2019; 143:1-16.

Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease.

Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.

An estimated 30.3 million Americans have type 2 diabetes (T2D), a complex, progressive disease that requires intensified treatment over time.^1-3 The complexity of T2D management, coupled with the need to tailor treatment recommendations to individual patients, presents an ongoing clinical challenge. The number and variety of treatment options available for T2D has increased dramatically in the last 15 years, with several new drug classes emerging as safe and effective.^2,4,5

A preliminary slate of candidates for the election of Officer positions for a one-year (1) term, five (5) open positions on the Board of Directors for election to a three-year (3) term (2019-2022) and one (1) open position on the Board of Directors for a one-year (1) term (2019-2020) to fill the unexpired term of Dr. Sethu Reddy, who was elected Secretary in 2018, was sent to the membership via email/fax on December 28.